Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma.

[1]  P. Wild,et al.  BioScore (B7-H1, survivin, and Ki-67) does not predict cancer-specific mortality in surgically treated patients with renal cell carcinoma: An external validation study. , 2019, Urologic oncology.

[2]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[3]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[4]  E. Plimack,et al.  Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Liang,et al.  Prognostic role of survivin in renal cell carcinoma: A system review and meta-analysis. , 2016, European journal of internal medicine.

[6]  Ken‐ichiro Yoshida,et al.  Higher preoperative serum levels of PD‐L1 and B7‐H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF‐targeted therapy and unfavorable prognosis of renal cell carcinoma , 2016, Cancer medicine.

[7]  Sean S. Park,et al.  T cell Bim levels reflect responses to anti-PD-1 cancer therapy. , 2016, JCI insight.

[8]  T. Choueiri,et al.  The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. , 2015, The Lancet. Oncology.

[9]  J. Cheville,et al.  Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long‐term follow‐up , 2013, BJU international.

[10]  K. Yorukoglu,et al.  Significance of P-glycoprotein, p53, and survivin expression in renal cell carcinoma. , 2011, Urologic oncology.

[11]  S. Boorjian,et al.  Survival after complete surgical resection of multiple metastases from renal cell carcinoma , 2011, Cancer.

[12]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[13]  C. Lohse,et al.  Development and evaluation of BioScore , 2009, Cancer.

[14]  R. Thompson,et al.  Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma , 2008, Clinical Cancer Research.

[15]  C. Lohse,et al.  External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma , 2008, Cancer.

[16]  J. Cheville,et al.  Ki‐67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other , 2007, Cancer.

[17]  J. Cheville,et al.  PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[18]  J. Cheville,et al.  High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma , 2006, Cancer.

[19]  J. Cheville,et al.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.

[20]  J. Cheville,et al.  A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. , 2005, The Journal of urology.

[21]  Alamdari,et al.  Follow‐up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy , 1999, BJU international.

[22]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.